AMERICAN MEDICAL ASSOCIATION ORGANIZED MEDICAL STAFF SECTION

Resolution: 3
(I-26)

Introduced by: Matthew Vo, MD

Subject: More Monitoring for GIP & GLP-1 Receptor Agonist Medications

Referred to: OMSS Reference Committee
(, MD, Chair)

Whereas, GIP and GLP-1 receptor agonist medications continue to be heavily advertised and touted as some kind of miracle drug for weight loss, besides their main indication as a treatment for diabetes, there are limited studies on the potential side-effects, especially those involving the senior (65 years and older) population, such as muscle loss (sarcopenia) and bone density loss; and

Whereas, the costs of these medications continue to be high and they can potentially cost the healthcare system a lot of money over the long run with Medicare now covering several; and

Whereas, there are no long-term studies of the potential side effects of these medications and there have been many alarming side effects reported; and

Whereas, there are no current recommendations to better safeguard patients taking these medications and patients are not required to be monitored by qualified health professionals,; therefore be it

RESOLVED, that our American Medical Association advocates that individuals using GIP and GLP-1 receptor agonist medications be regularly monitored by qualified healthcare professionals for occurrence of medication-related side effects as well as benefits (Directive to Take Action); and be it further

RESOLVED, that our AMA amend Policy D-100.960 to read as follows:

> Our AMA supports and calls for a registry of GIP and GLP-1 receptor agonists' side effects, as well as potential impacts on pregnancy and patients older than 65.

(Modify Current HOD Policy).

Fiscal Note: (Assigned by HOD)

Received: 7/29/2026

REFERENCES

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/
2. https://www.ncbi.nlm.nih.gov/books/NBK603723/
3. https://jamanetwork.com/journals/jama/fullarticle/2810542
4. https://www.medicare.gov/coverage/weight-loss-drugs
5. https://www.healthline.com/health-news/ozempic-muscle-mass-loss
6. https://www.everydayhealth.com/obesity/what-older-adults-need-to-know-before-taking-a-glp-1-like-ozempic/
7. https://www.medscape.com/viewarticle/semaglutide-linked-rare-brain-illness-2026a1000npa?reg=1
8. https://www.clinicalnutritionjournal.com/article/S0261-5614(25)00351-6/fulltext

RELEVANT AMA POLICY

Creating a Registry of Potential Side Effects of GIP & GLP-1 Medications D-100.960

Our AMA supports and calls for a registry of GIP and GLP-1 receptor agonists' side effects, as well as potential impacts on pregnancy.

Citation: Rep 516, A-25